$CHRS
Coherus BioSciences, Inc.

2017 Q3 Form 10-Q Financial Statement

#000156459017021844 Filed on November 06, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $0.00 $162.8M
YoY Change -100.0% 2172.01%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.00M $13.60M
YoY Change 2.94% 33.33%
% of Gross Profit
Research & Development $42.63M $64.57M
YoY Change -33.99% -5.34%
% of Gross Profit
Depreciation & Amortization $800.0K $800.0K
YoY Change 0.0% 14.29%
% of Gross Profit
Operating Expenses $56.62M $78.22M
YoY Change -27.62% -0.21%
Operating Profit $84.62M
YoY Change -218.82%
Interest Expense $2.392M $2.420M
YoY Change -1.16% 7233.33%
% of Operating Profit 2.86%
Other Income/Expense, Net $14.00K $1.600M
YoY Change -99.13% -780.85%
Pretax Income -$59.00M $83.80M
YoY Change -170.41% -217.2%
Income Tax
% Of Pretax Income
Net Earnings -$58.99M $83.94M
YoY Change -170.28% -217.67%
Net Earnings / Revenue 51.55%
Basic Earnings Per Share -$1.09 $1.93
Diluted Earnings Per Share -$1.09 $1.67
COMMON SHARES
Basic Shares Outstanding 54.07M 43.47M
Diluted Shares Outstanding 54.07M 51.58M

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $150.1M $159.7M
YoY Change -6.01% 3.9%
Cash & Equivalents $135.6M $159.7M
Short-Term Investments $14.50M
Other Short-Term Assets $21.60M $17.20M
YoY Change 25.58% -51.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $171.6M $177.3M
YoY Change -3.21% -6.34%
LONG-TERM ASSETS
Property, Plant & Equipment $13.80M $10.70M
YoY Change 28.97% 23.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $800.0K $800.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $18.20M $15.10M
YoY Change 20.53% 16.17%
TOTAL ASSETS
Total Short-Term Assets $171.6M $177.3M
Total Long-Term Assets $18.20M $15.10M
Total Assets $189.8M $192.4M
YoY Change -1.35% -4.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.10M $22.90M
YoY Change -55.9% -9.13%
Accrued Expenses $16.70M $24.90M
YoY Change -32.93% -1.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.40M $58.40M
YoY Change -46.23% -29.21%
LONG-TERM LIABILITIES
Long-Term Debt $101.3M $99.90M
YoY Change 1.4%
Other Long-Term Liabilities $2.200M $2.300M
YoY Change -4.35% -97.12%
Total Long-Term Liabilities $103.5M $102.2M
YoY Change 1.27% 28.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.40M $58.40M
Total Long-Term Liabilities $103.5M $102.2M
Total Liabilities $133.6M $159.5M
YoY Change -16.24% -1.36%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $56.20M $32.90M
YoY Change
Total Liabilities & Shareholders Equity $189.8M $192.4M
YoY Change -1.37% -4.89%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$58.99M $83.94M
YoY Change -170.28% -217.67%
Depreciation, Depletion And Amortization $800.0K $800.0K
YoY Change 0.0% 14.29%
Cash From Operating Activities -$41.50M -$62.00M
YoY Change -33.06% 3.85%
INVESTING ACTIVITIES
Capital Expenditures -$1.800M -$500.0K
YoY Change 260.0% -79.17%
Acquisitions
YoY Change
Other Investing Activities $30.60M $0.00
YoY Change -100.0%
Cash From Investing Activities $28.70M -$500.0K
YoY Change -5840.0% -84.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 75.10M 1.300M
YoY Change 5676.92% -87.62%
NET CHANGE
Cash From Operating Activities -41.50M -62.00M
Cash From Investing Activities 28.70M -500.0K
Cash From Financing Activities 75.10M 1.300M
Net Change In Cash 62.30M -61.20M
YoY Change -201.8% 16.79%
FREE CASH FLOW
Cash From Operating Activities -$41.50M -$62.00M
Capital Expenditures -$1.800M -$500.0K
Free Cash Flow -$39.70M -$61.50M
YoY Change -35.45% 7.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
892000
CY2017Q3 us-gaap Minority Interest
MinorityInterest
-1288000
CY2017Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
54907000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189758000
CY2017Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
2417000
CY2016Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
3714000
CY2017Q3 us-gaap Related Party Transaction Due From To Related Party Current
RelatedPartyTransactionDueFromToRelatedPartyCurrent
0
CY2017Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1499000
CY2016Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
162835000
CY2017Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
75944000
CY2017Q3 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
25314000
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.93
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.67
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54070872
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43469986
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54070872
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51581298
CY2017Q3 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0
CY2016Q3 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
30000
CY2017Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
598000
CY2016Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
590000
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
150000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
723000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-1300000
us-gaap Share Based Compensation
ShareBasedCompensation
25065000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-47000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
464000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
8000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1859000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1141000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-18111000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3579000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9198000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-872000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-9873000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1562000
chrs Increase Decrease In Advance Payments Under License Agreement
IncreaseDecreaseInAdvancePaymentsUnderLicenseAgreement
-1070000
chrs Increase Decrease In Contingent Liability To Collaborator
IncreaseDecreaseInContingentLiabilityToCollaborator
-66255000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
332000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
14000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-170364000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-165653000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4464000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2949000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
74344000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
60000000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-18808000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
75000000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
25000000
chrs Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts And Commissions
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsAndCommissions
199866000
chrs Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts And Commissions
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsAndCommissions
69472000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
739000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
415000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
510000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
199895000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
170180000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-113000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-127000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10610000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1451000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
158226000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159677000
us-gaap Nature Of Operations
NatureOfOperations
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization and Operations<font style="font-weight:normal;"> </font></p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of the Business </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coherus BioSciences, Inc. (the &#8220;Company&#8221;, &#8220;Coherus&#8221;, &#8220;we&#8221;, our&#8221; or &#8220;us&#8221;) is a late-stage clinical biologics platform company, focused on the global biosimilar market. The Company&#8217;s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively.&nbsp;&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Need to Raise Additional Capital<font style="font-weight:normal;"> </font></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2017, the Company had an accumulated deficit of $726.4 million and cash and cash equivalents and investments in marketable securities of $150.1 million. In January 2017, the Company issued and sold 148,827 shares of common stock at a weighted average price of $28.88 per share through its ATM Offering Program and received total net proceeds of $4.2 million, and in February and March 2017, the Company issued and sold 5,294,902 shares of common stock at a price of $24.25 per share from its underwritten follow-on offering and received total net proceeds of $120.4 million (see Note 8). In August 2017, the Company completed a private placement transaction with V-Sciences Investments Pte Ltd, a private limited Singapore company (&#8220;Temasek&#8221;), where it sold an aggregate of 6,556,116 shares of common stock at a purchase price of $11.4397 per share for aggregate gross proceeds of $75.0 million. After deducting offering expense of $0.1 million, the net proceeds were $74.9 million (see Note 8). </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its current available cash and cash equivalents and investments in marketable securities will be sufficient to fund its planned expenditures and meet the Company&#8217;s obligations <font style="color:#000000;">for at least 12 months following its financial statement issuance date</font><font style="color:#1F497D;">. </font>The Company will need to raise additional funds in the future; however there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable. If the Company is unable to obtain adequate financing when needed, it may have to delay, reduce the scope of or suspend one or more of its clinical trials, research and development programs or commercialization efforts.</p></div>
CY2017Q3 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
9937000
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5575000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1193000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, valuation of deferred tax assets, impairment of goodwill and long-lived assets, the valuation of acquired intangible assets, clinical trial accruals, revenue recognition period, contingent consideration, convertible notes valuation, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.&nbsp;&nbsp;</p></div>
CY2017Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
150100000
CY2017Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-66000
CY2016Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-45000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-60000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-401000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
162835000
us-gaap Sales Revenue Net
SalesRevenueNet
1556000
us-gaap Sales Revenue Net
SalesRevenueNet
189262000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
0
CY2016 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
0
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
0
CY2016 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
0
CY2017Q3 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
82000
us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
286000
CY2017Q3 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
14000
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
55000
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22616000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16798000
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8825000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6026000
CY2017Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2016Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2016Q4 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
16039000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6945000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1496000
CY2017Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1400000
CY2017Q3 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-58989000
CY2016Q3 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
83939000
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-189103000
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-51416000
CY2016Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
2361000
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-58989000
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
86300000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-189103000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-51416000
CY2016Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3637441
CY2016Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
4473871
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16046122
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4989524
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16046122
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14494432
CY2017Q2 us-gaap Restructuring Charges
RestructuringCharges
3600000
CY2017Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
1500000
CY2017Q3 us-gaap Restructuring Reserve
RestructuringReserve
600000

Files In Submission

Name View Source Status
0001564590-17-021844-index-headers.html Edgar Link pending
0001564590-17-021844-index.html Edgar Link pending
0001564590-17-021844.txt Edgar Link pending
0001564590-17-021844-xbrl.zip Edgar Link pending
chrs-10q_20170930.htm Edgar Link pending
chrs-20170930.xml Edgar Link completed
chrs-20170930.xsd Edgar Link pending
chrs-20170930_cal.xml Edgar Link unprocessable
chrs-20170930_def.xml Edgar Link unprocessable
chrs-20170930_lab.xml Edgar Link unprocessable
chrs-20170930_pre.xml Edgar Link unprocessable
chrs-ex102_559.htm Edgar Link pending
chrs-ex311_6.htm Edgar Link pending
chrs-ex312_7.htm Edgar Link pending
chrs-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending